Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epi-RCHOP: Tazemetostat + R-CHOP in Newly Diagnosed DLBCL or High Risk FL
NCT02889523Phase 2Active, not recruiting
- Sponsor
- LYSARC
- Start
- Oct 2016
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of tazemetostat in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by LYSARC. Started Oct 2016; status: active, not recruiting.
02
Drugs
tazemetostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02889523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02889523.